Small pools, big ideas: How the rare disease community is reimagining clinical trials
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients has inherently been unfeasible for the rare disease community.
By FierceBiotech
· Apr 17, 2026
· via FierceBiotech
Image: FierceBiotech
Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
PipelineFierceBiotech ↗
Qiagen has moved into syndromic testing for bloodstream infections with the launch of its newest offering.…
PipelineFierceBiotech ↗
While fentanyl overdose deaths have been falling in recent years, use of the drug remains a major public healt…
PipelineFierceBiotech ↗
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clin…